Harrelson's Own Side Effects: What the Science Actually Shows - Mustaf Medical
Harrelson's Own Side Effects: What the Science Actually Shows
This article does not endorse, recommend, or rank any specific product. It examines the scientific research on the compounds associated with Harrelson's Own for informational purposes only. Products marketed as Harrelson's Own have been reported to contain cannabidiol (CBD) extracted from hemp, often labeled as "full‑spectrum" or "broad‑spectrum." Below we break down what the research says about those ingredients, how they work in the body, and what side‑effect data actually exist.
Background
What's inside?
Harrelson's Own products typically list cannabidiol (CBD) as the primary cannabinoid. Full‑spectrum versions may also contain trace amounts of other phytocannabinoids such as cannabigerol (CBG) and cannabinol (CBN), plus terpenes like myrcene and limonene. Isolate formulations, when offered, contain only pure CBD without other cannabinoids or terpenes.
How is it made?
Most manufacturers use CO₂ supercritical extraction, a method that preserves delicate compounds while removing unwanted plant waxes and chlorophyll. The extract is then either mixed into carrier oils (like MCT or hemp seed oil) for tinctures, blended into gummy bases, or infused into creams for topical use. These processes affect bioavailability: sublingual oils are absorbed within 15‑45 minutes, gummies take 1‑2 hours, and topicals stay largely on the skin.
Legal backdrop
The 2018 Farm Bill makes hemp‑derived CBD legal in the United States so long as the THC content stays below 0.3 % by dry weight. State laws differ; a few states still restrict sales of any CBD product. The Food and Drug Administration (FDA) has approved only one CBD medication-Epidiolex-for rare seizure disorders. All other CBD products, including those from Harrelson's Own, are sold as dietary supplements and cannot legally claim to diagnose, treat, cure, or prevent disease.
Research timeline
Early animal work in the 1990s hinted that CBD might modulate pain and anxiety pathways. Human trials began in earnest after 2015, focusing on anxiety, pain, sleep, and epilepsy. Most studies are small (n < 100), short‑term (≤12 weeks), and funded by a mix of academic and industry sources. The overall evidence quality ranges from Preliminary to Moderate depending on the outcome measured.
Mechanisms
The endocannabinoid system in plain language
Think of the endocannabinoid system (ECS) as the body's internal "balance board." It helps regulate mood, pain, sleep, and immune responses. Two main receptors do the heavy lifting:
- CB1 receptors – mostly in the brain and nervous system, they influence mood, memory, and pain perception.
- CB2 receptors – found mainly on immune cells, they help tone down inflammation.
Your body also produces its own cannabinoids-anandamide and 2‑arachidonoylglycerol (2‑AG)-that naturally bind these receptors. Enzymes like fatty‑acid amide hydrolase (FAAH) break them down, keeping the system in check.
How CBD (the main ingredient in Harrelson's Own) interacts
CBD does not bind strongly to CB1 or CB2. Instead, it nudges the ECS in several indirect ways:
| Pathway | What it does | Evidence label |
|---|---|---|
| FAAH inhibition | Slows the breakdown of anandamide, modestly boosting its level → may enhance mood and reduce pain perception | [Preliminary] |
| 5‑HT1A agonism | Acts on a serotonin receptor linked to anxiety relief → can calm the amygdala's "fear center" | [Early Human] |
| TRPV1 desensitization | Dampens a pain‑related ion channel → may reduce peripheral pain signals | [Preliminary] |
| Modulation of cytokine release | Lowers pro‑inflammatory molecules like TNF‑α and IL‑6 via CB2‑related pathways → contributes to anti‑inflammatory effects | [Moderate] |
| Entourage effect (full‑spectrum only) | Small amounts of other cannabinoids and terpenes may work together to enhance overall activity, though the mechanism is still speculative | [Preliminary] |
Dose matters – what studies actually used
Most human trials use oral doses of 300‑600 mg of CBD per day. That's far higher than the typical 10‑30 mg per serving found in over‑the‑counter tinctures and gummies. For example, a 2019 double‑blind RCT in Journal of Clinical Psychology gave participants 400 mg CBD daily for 4 weeks and observed a modest reduction in generalized anxiety scores (effect size = 0.35) - labeled [Early Human].
In contrast, a 2020 open‑label study of 20 mg CBD oil taken twice daily for two weeks reported no statistically significant change in pain ratings among 30 participants with mild osteoarthritis - a Preliminary finding that underscores the dose‑gap problem.
Delivery method differences
- Sublingual oil – bypasses the digestive tract, so blood levels rise quickly (15‑45 min). This aligns better with the pharmacokinetics used in most oral‑dose trials.
- Gummies – must be digested; peak plasma concentrations appear 1‑2 hours after ingestion, and the dose is often spread over a larger food matrix, which can lower bioavailability by 30‑40 %.
- Topicals – cannabinoids stay mostly in the skin; they can engage local CB2 receptors to reduce inflammation, but systemic effects are minimal.
Because most clinical data rely on oral capsules or oils, results from gummy or topical studies are harder to compare directly.
Full‑spectrum vs. isolate
Full‑spectrum Harrelson's Own products contain a cocktail of cannabinoids and terpenes, whereas isolates are pure CBD. The "entourage effect" hypothesis suggests the mixture might be more effective than CBD alone, but human evidence remains Preliminary. One 2021 crossover trial in Frontiers in Pharmacology (n = 24) found a slight improvement in sleep quality with full‑spectrum oil versus isolate, but the difference was not statistically significant (p = 0.08).
Bottom line on mechanism
The biology behind CBD makes sense-its indirect actions on the ECS can plausibly influence pain, anxiety, and inflammation. However, mechanistic plausibility does not equal proven therapeutic benefit. Most human data involve small groups and short follow‑up periods, and the doses used in research often exceed what everyday consumers take.
Who Might Consider Harrelson's Own
Typical user profiles
- A busy professional with mild stress – looking for a non‑sedating way to calm daily nervousness without prescription medication.
- A middle‑aged adult with occasional joint discomfort – interested in a natural supplement that may reduce inflammation after light exercise.
- A sleep‑conscious student – experimenting with a low‑dose nighttime CBD gummy to see if it eases bedtime wind‑down.
- An older adult on multiple prescriptions – cautiously exploring CBD after discussing potential drug interactions with a pharmacist.
These profiles are illustrative; they do not constitute medical advice or a recommendation to start using any product.
Comparative Table & Context
| Compound / Product | Primary Mechanism | Compound Type | Typical Delivery | Studied Dose* | Evidence Level | Key Limitation | Drug Interaction Risk | Legal Status |
|---|---|---|---|---|---|---|---|---|
| Harrelson's Own (full‑spectrum CBD) | FAAH inhibition, 5‑HT1A agonism, CB2‑mediated anti‑inflammation | Full‑spectrum cannabinoid blend | Oil / Gummies / Cream | 300‑600 mg oral (clinical) | Moderate for anxiety, Preliminary for pain | Dose gap vs. OTC products | Moderate (CYP450 inhibition) | Legal if <0.3 % THC |
| Naproxen (NSAID) | COX‑1/COX‑2 inhibition → ↓ prostaglandins | Synthetic anti‑inflammatory | Oral tablet | 250‑500 mg per dose | Established for pain | GI irritation, cardiovascular risk | Low | Prescription/OTC |
| Curcumin (turmeric extract) | NF‑κB pathway modulation → ↓ cytokines | Plant polyphenol | Capsules | 500‑1000 mg daily | Preliminary for inflammation | Poor bioavailability | Low | Legal |
| Magnesium glycinate | NMDA receptor modulation → muscle relaxation | Mineral supplement | Oral capsule | 200‑400 mg elemental Mg | Moderate for sleep quality | May cause diarrhea at high dose | Low | Legal |
| CBG (cannabigerol) | CB2 agonism → anti‑inflammatory | Minor cannabinoid | Oil | 30‑100 mg daily (early trials) | Early Human (pain) | Limited human data | Moderate (CYP450) | Legal if hemp‑derived |
*Studied doses reflect amounts used in peer‑reviewed human trials, not typical consumer servings.
Population considerations
- Age – Most CBD studies enroll adults aged 18‑65. Pediatric data are limited to Epidiolex.
- Health status – Trials often exclude people with severe liver disease or uncontrolled psychiatric conditions.
Delivery method comparison
Oral oils reach systemic circulation faster than gummies, which may affect the timing of any perceived benefit. Topicals act locally and are useful when the goal is targeted skin or joint relief, but they will not produce the broader ECS modulation seen with oral routes.
Full‑spectrum vs. isolate vs. broad‑spectrum
- Full‑spectrum – contains THC (≤0.3 %), other cannabinoids, and terpenes.
- Broad‑spectrum – same as full‑spectrum but THC‑free.
- Isolate – pure CBD.
Human evidence distinguishing these formats is Preliminary. If you are sensitive to THC, a broad‑spectrum or isolate may be preferable.
Safety
Common side effects – In clinical trials, the most frequently reported adverse events were mild and dose‑dependent: dry mouth (≈12 % at 600 mg), dizziness (≈8 %), and gastrointestinal upset such as diarrhea (≈6 %). These rates drop substantially at the 10‑30 mg doses typical of many over‑the‑counter products.
Drug interactions – CBD inhibits several cytochrome P450 enzymes, notably CYP3A4 and CYP2C19. This can raise blood levels of medications metabolized by these pathways, including warfarin, certain antiepileptics (e.g., clobazam), and some SSRIs. The FDA issued a warning in 2019 about the potential for CBD to increase liver enzymes and interact with prescription drugs.
Special populations
- Pregnancy & breastfeeding – The FDA recommends avoiding CBD due to insufficient safety data.
- Liver disease – High‑dose CBD (≥1,200 mg/day) has been linked to elevated liver enzymes in epilepsy trials.
- Children – Only Epidiolex is approved for pediatric use; other CBD products are not studied in this group.
Long‑term safety gaps – Most human studies last 12 weeks or less. Evidence on chronic daily use beyond six months is sparse, making it difficult to predict rare or cumulative adverse events.
When to See a Doctor
If you experience any of the following while using CBD, seek medical advice: persistent nausea, unexplained bruising, sudden mood changes, or signs of liver trouble (e.g., yellowing of skin or eyes).
FAQ
1. How does CBD interact with the body's endocannabinoid system?
CBD indirectly influences the ECS by inhibiting the enzyme FAAH, which raises natural anandamide levels, and by acting as a weak agonist at the 5‑HT1A serotonin receptor. These actions can modestly affect mood and pain perception. Evidence ranges from Preliminary (FAAH inhibition) to Early Human (5‑HT1A effects on anxiety).
2. Are the side effects reported for Harrelson's Own serious?
Most reported side effects are mild-dry mouth, drowsiness, or slight gastrointestinal upset. They are dose‑dependent and uncommon at the low daily doses found in most retail CBD products. High‑dose clinical studies have noted liver enzyme elevation, but these doses far exceed typical consumer use.
3. Can CBD replace my prescription pain or anxiety medication?
No. CBD is not FDA‑approved for pain or anxiety (except Epidiolex for rare seizures). It may be used as a complementary supplement, but you should keep your prescribing clinician informed, especially because CBD can interact with drugs metabolized by CYP450 enzymes.
4. What does "full‑spectrum" mean, and is it better than isolate?
Full‑spectrum refers to a CBD extract that contains a range of cannabinoids, terpenes, and up to 0.3 % THC. Some researchers propose an "entourage effect" where these compounds work synergistically, but human evidence is still Preliminary. Isolate offers pure CBD with no THC or other cannabinoids, which may be preferable for people sensitive to THC.
5. Is Harrelson's Own legal in my state?
If the product contains less than 0.3 % THC and is derived from industrial hemp, it is federally legal under the 2018 Farm Bill. However, a handful of states have stricter regulations, so you should verify local laws before purchasing.
6. How long does it take to feel any effect from a CBD gummy?
Because gummies must be digested, plasma CBD levels typically peak 1‑2 hours after consumption. Users often report subtle relaxation or improved sleep onset within that window, but individual response varies widely.
7. Should I worry about drug interactions if I'm on multiple medications?
Yes. CBD can inhibit CYP3A4 and CYP2C19, potentially raising levels of many prescription drugs. If you take anticoagulants, anti‑epileptics, or other medications with a narrow therapeutic window, consult a healthcare professional before adding CBD.
Key Takeaways
- Harrelson's Own products mainly contain CBD, sometimes with other minor cannabinoids in full‑spectrum blends.
- The scientific evidence for CBD's effects on anxiety, pain, and inflammation is modest and often based on high doses far above typical consumer servings.
- Common side effects are mild and dose‑dependent; liver enzyme changes occur only at very high clinical doses.
- CBD can interact with drugs metabolized by CYP450 enzymes, so discuss use with a clinician, especially if you take prescription meds.
- Federal law permits hemp‑derived CBD under 0.3 % THC, but state regulations vary; no CBD product (including Harrelson's Own) is FDA‑approved for general wellness.
A Note on Sources
Key findings come from peer‑reviewed journals such as Journal of Clinical Psychology, Frontiers in Pharmacology, and Cannabis and Cannabinoid Research, as well as regulatory guidance from the FDA and NIH. Reputable health outlets like the Mayo Clinic have summarized the current understanding of CBD's safety profile. Readers can search PubMed using terms like "cannabidiol," "CBD," and "full-spectrum" to explore the primary literature.
Disclaimer: This content is for informational purposes only. Always consult a healthcare professional before starting any CBD or cannabinoid supplement, especially if you take medications or have an existing health condition.